Delaware
|
000-32501
|
33-0827593
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer Identification Number)
|
o |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR
240.13e-4(c))
|
(a) |
Not
applicable.
|
(b) |
2.1 Pro
forma financial information.
|
(c) |
Not
applicable.
|
(d) |
99.1 Cytori
Therapeutics, Inc. press release dated June 1,
2007.
|
CYTORI THERAPEUTICS, INC. | |
Date: June 5, 2007 | By: /s/ Christopher J. Calhoun |
Christopher J. Calhoun | |
Chief Executive Officer |
Exhibit
|
|
2.1
|
Pro
forma financial information.
|
99.1
|
Cytori
Therapeutics, Inc. press release dated June 1,
2007.
|